1. Academic Validation
  2. Muscarinic interactions of bisindolylmaleimide analogues

Muscarinic interactions of bisindolylmaleimide analogues

  • Eur J Pharmacol. 1998 Nov 6;360(2-3):281-4. doi: 10.1016/s0014-2999(98)00707-9.
S Lazareno 1 A Popham N J Birdsall
Affiliations

Affiliation

  • 1 MRC Collaborative Centre, London, UK. s-lazare@nimr.mrc.ac.uk
Abstract

We have used radioligand binding studies to determine the affinities of seven bisindolylmaleimide analogues, six of which are selective inhibitors of protein kinase C, at human muscarinic M1-M4 receptors. The compounds were most potent at M1 receptors, and Ro-31-8220 was the most potent analogue, with a Kd of 0.6 microM at M1 receptors. The weakest compounds, bisindolylmaleimide IV and bisindolylmaleimide V, had Kd values of 100 microM. If it is necessary to use protein kinase C inhibitors at concentrations of 10 microM or more in studies involving muscarinic receptors then bisindolylmaleimide IV may be the most appropriate inhibitor to use.

Figures
Products